Caveolin-1 promotes Rfng expression via Erk-Jnk-p38 signaling pathway in mouse hepatocarcinoma cells

Caveolin-1通过Erk-Jnk-p38信号通路促进小鼠肝癌细胞中Rfng的表达

阅读:8
作者:Cheng Zhang, Qiong Wu, Huang Huang, Xixi Chen, Tianmiao Huang, Wenli Li, Yubo Liu, Jianing Zhang

Abstract

Caveolin-1 (Cav-1) is a critical structural protein of caveolae and plays an oncogene-like role by participating in abnormal protein glycosylation in hepatocellular carcinoma (HCC). However, the mechanism by which Cav-1 regulates glycosylation and glycosyltransferase expression has not been completely defined. Here, we show that Cav-1 promotes the expression of Rfng, which is a β-1,3-N-acetylglucosaminyltransferase included in the Fringe family. In this study, we showed that the mouse HCC cell line, Hepa1-6, with low Rfng transcription and protein levels, lacked Cav-1 expression, whereas strong Rfng expression was found in the mouse HCC cell line Hca-F, with high transcription and protein levels for Cav-1. Subsequently Cav-1 overexpression in Hepa1-6 was found to activate mitogen-activated protein kinase (MAPK) signaling and induce phosphorylation of the transcription factors Hnf4a and Sp1, which bind to the Rfng promoter region to promote its transcription. On the contrary, when knocking down Cav-1 expression in Hca-F, the activity of the MAPK pathway was significantly inhibited, and phosphorylation of Hnf4a, Sp1 and the expression of Rfng were attenuated. These data reveal that Cav-1 promotes phosphorylation of transcription factors Hnf4a and Sp1, which bind to the Rfng promoter region, via the MAPK signaling pathway, to induce the transcription of Rfng. Our current findings provide molecular genetic evidence that Cav-1 plays an important role in regulating glycosyltransferase expression and may participate in the abnormal glycosylation that mediates the invasion and metastasis of HCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。